Calquence (acalabrutinib)
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for Calquence (acalabrutinib), covering 2022-05-06 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]